Samsung Bioepis announces new data from Ph III clinical study of Byooviz® (ranibizumab biosimilar)

Sep 9, 2021

Samsung Bioepis announced results from a post-hoc and subgroup analysis of a Ph III clinical study of Byooviz® (ranibizumab biosimilar). Samsung Bioepis reported that the data supports biosimilarity between Byooviz® and reference ranibizumab.

Print Page Mail Article